US Stock MarketDetailed Quotes
ABVC ABVC BioPharma
- 0.6413
- +0.0513+8.69%
Close Jan 2 16:00 ET
8.32MMarket Cap-0.79P/E (TTM)
0.6900High0.5900Low157.01KVolume0.5900Open0.5900Pre Close98.55KTurnover1.65%Turnover RatioLossP/E (Static)12.98MShares1.730052wk High1.00P/B6.10MFloat Cap0.405352wk Low--Dividend TTM9.50MShs Float116.9000Historical High--Div YieldTTM16.95%Amplitude0.4053Historical Low0.6270Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
ABVC BioPharma Stock Forum
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21
Thursday, 19th December at 8:30 am
FREMONT, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced in response to the discontinuation of Prozac[...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
GlobeNewswire· 21 mins ago
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
Wednesday, 11th December at 6:30 am
FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioP...
No comment yet